Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab in ApoE4 Carrier Mild to Moderate Alzheimer's Disease
NCT00575055Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2007
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bapineuzumab in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 18 months and Disability Assessment for Dementia at 18 months. Started Dec 2007; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00575055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00575055.